

**Press Release April 3, 2020**

## **Infant Bacterial Therapeutics AB postpones Annual General Meeting**

Due to the difficulty of gathering in larger groups, caused by the Corona Epidemic, IBT's Board of Directors has decided to postpone the Annual General Meeting until June 16, 2020, instead of the originally planned date of May 11, 2020.

Notice of the Annual General Meeting will be sent out no later than four weeks before the new date.

### ***About Infant Bacterial Therapeutics AB***

Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis ("NEC") and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance *Lactobacillus reuteri*, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Infant Bacterial Therapeutics AB ("IBT") is a public company domiciled in Stockholm. The company's class B-shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

### **For additional information please contact**

Staffan Strömberg, CEO

Daniel Mackey, CFO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 70 670 1226

[info@ibtherapeutics.com](mailto:info@ibtherapeutics.com)

[www.ibtherapeutics.com](http://www.ibtherapeutics.com)